CHONGQING LUMMY PHARMACEUTICAL CO., LTD.

Chongqing Lummy Pharmaceutical Co., Ltd.

300006

CNE100000H10

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
2.91 ^CNY	-3.00%		-1.69%	-21.77%

04-23	Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Chengdu Xindu District Cundetang Pharmacy Co., Ltd. announced that it has received $7.800000 million in funding from KIP China, Chongqing Lummy Pharmaceutical Co., Ltd. and another investor.

November 25, 2021

Chengdu Xindu District Cundetang Pharmacy Co., Ltd. announced that it has received $7,800,000 in funding on November 26, 2021. The transaction included participation from KIP China, Chongqing Lummy Pharmaceutical Co., Ltd., and Xingtong Ventures.

Latest news about Chongqing Lummy Pharmaceutical Co., Ltd.

Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug	03-18	MT
Lummy Pharma Gets Nod to Market Nicorandil	03-04	MT
Lummy Pharmaceutical's Ramosetron Hydrochloride Injection Passes Regulatory Evaluation	11-10	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-20	CI
Lummy Pharmaceutical's Unit Gets Nod to Trial Ovarian Cancer Drug; Shares Surge 20%	23-09-15	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Chongqing Lummy Pharmaceutical's Cancer Drug Passes Regulatory Evaluation	23-07-07	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Chongqing Lummy Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding	23-03-15	CI
Lummy Pharma Unit Gets Regulatory Nod in China for Liver Cirrhosis Drug	23-01-02	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:300006) dropped from S&P Global BMI Index	22-06-20	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI
Chengdu Xindu District Cundetang Pharmacy Co., Ltd. announced that it has received $7.800000 million in funding from KIP China, Chongqing Lummy Pharmaceutical Co., Ltd. and another investor.	21-11-25	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:300006) added to S&P Global BMI Index	21-09-20	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-30	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2020	21-04-21	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-18	CI
Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. for approximately CNY 200 million.	21-03-11	CI

Chart Chongqing Lummy Pharmaceutical Co., Ltd.

Duration

Period

Chart Chongqing Lummy Pharmaceutical Co., Ltd.

More charts

Company Profile

Chongqing Lummy Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of medicines. The Companyâs medicines consist of anti-infection medicines, special medicines, infusion, Chinese patent drugs and herbal decoction pieces. The Company's main products include carbon nanoparticles suspension injection, omeprazole enteric capsules, mycobacterium phlei F.U.36 injection, levofloxacin hydrochloride and tranexamic acid and sodium chloride injection, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-09-01 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHONGQING LUMMY PHARMACEUTICAL CO., LTD.	-21.77%	438M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals

Chongqing Lummy Pharmaceutical Co., Ltd.

Equities

300006

CNE100000H10

Pharmaceuticals

Chengdu Xindu District Cundetang Pharmacy Co., Ltd. announced that it has received $7.800000 million in funding from KIP China, Chongqing Lummy Pharmaceutical Co., Ltd. and another investor.

Latest news about Chongqing Lummy Pharmaceutical Co., Ltd.

Chart Chongqing Lummy Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals